PRPO logo

PRECIPIO INC

PRPONASDAQ
🏆 #4440 by market capEarnings Nov 16US Equity
$18.69▼ $0.98 (−4.96%)
Pre-market · at close
🔔
Track PRPO
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.0%
7d▼ 9.9%
14d▼ 15.8%
30d▼ 19.8%
ytd▼ 19.5%
1y▼ 12.6%
🏦Market Cap
$33M
Small Cap
📈Revenue Growth (YoY)
28.0%
High Growth
📊Gross Margin
44.1%
Healthy
💵FCF Margin
3.1%
Moderate
⚖️P/S Ratio
1.2x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$18.68 – $19.38
52-Week Range
$18.50 – $33.63
Volume (shares)
876
Avg Volume (shares)
—
Shares Outstanding
1.8M
Next Earnings
2026-11-16

Fundamentals Snapshot

Annual Revenue
$24M
Last Q Revenue
$7M
P/E Ratio
—
P/S Ratio
1.2x
EPS (TTM)
$-0.68
Dividend Yield
—
Dilution (1yr)
+7.5%
PRPO logo

PRECIPIO INC

PRPO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$24M▲ +50.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.5%▼ −6.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$1M▼ −71.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$359K▲ +66.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.6M▲ +7.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▲ +$2M YoY
StockOtter · stockotter.space

About PRECIPIO INC

Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Jun 2024

Latest News & Updates

News unavailable.